There's a misconception that has circulated among SMEs for at least twenty years, and it's one of those misconceptions that, instead of clearing up over time, has solidified. The misconception concerns the FDA — the Food and Drug Administration, the US federal agency that regulates food, drugs, medical devices, and cosmetics for the American market. The misconception is simple in form and costly in substance: many companies are convinced that "being FDA registered" is a quality certification, a seal attesting that the product has been examined, evaluated, and approved by the American authority. They tell it in their commercial materials, they say it to customers, they wave it in presentations as proof of reliability.
It isn't so. FDA registration certifies nothing. It doesn't guarantee quality, doesn't validate processes, doesn't express judgments on the product. It's an administrative act that allows the company to operate legally on the American market for the regulated categories. Thinking of FDA registration as a certification is like thinking of a car's license plate as a certificate of speed: the plate lets the vehicle circulate, it says nothing about how it performs. Confusing the two things leads to mistaken commercial behaviors — both in those who boast of an approval that gives them no competitive advantage, and in those who presume to have done the work when they've only opened the door.
The mistake is particularly widespread among those exporting to the United States for the first time or considering doing so. It's worth clarifying well what FDA registration is, what it isn't, and what it really takes to build lasting market positions on the American market for products subject to FDA regulation.
What the FDA really does, and what it doesn't
The Food and Drug Administration is the federal agency that has regulatory authority over about twenty percent of the US consumer economy. It's an agency of oversight and regulatory enforcement, not a certification body. The distinction is substantial.
What the FDA does. It publishes the rules that companies must comply with to place regulated products on the American market. It maintains the registration databases of companies and products. It conducts inspections at facilities, both American and foreign. It seizes non-compliant goods on entry into the United States. It sanctions, up to withdrawal from the market, companies that violate the regulations. It publishes safety notices, recalls dangerous products, specifically authorizes drugs and medical devices after formal evaluation procedures.
What the FDA doesn't do. It doesn't issue quality certificates to products. It doesn't pre-evaluate most products subject to registration (the exception being drugs and high-class medical devices, which have specific authorization procedures). It doesn't confer seals or marks that can be used for commercial purposes. It doesn't guarantee that a registered product is better than an unregistered one — it simply verifies that those operating on the American market do so according to the rules.
The practical consequence is one: "FDA registered" on your commercial materials communicates nothing particularly positive to the informed American customer. It only communicates "this company operates legally on the American market for the regulated categories," which is the minimum prerequisite for being there. Communicating it as if it were a competitive advantage signals, paradoxically, little familiarity with the market — an experienced American customer reads the statement as naive, and wonders what else the counterpart doesn't know.
The regulated categories and what registering means for each
The four large categories under FDA jurisdiction have specific rules significantly different from one another. It's worth articulating the specifics, because they're often confused.
Food and beverages. Foreign companies that export food and beverages to the United States must register each production facility in the FDA Facility Registration Database and renew the registration every two years. They must also appoint a US Agent as the official point of contact with the FDA. For each shipment, a Prior Notice is required before arrival in the United States. The main regulatory framework is the Food Safety Modernization Act (FSMA), which has reoriented the entire US food regulation toward a preventive approach based on risk analysis — it significantly changes the way producers must document their processes.
Recent developments in the food sector have introduced additional requirements on product traceability, particularly for high health-risk categories. For Italian companies that export premium agri-food to the United States, the documentary requirements are progressively more sophisticated, and the ability to respond to FDA audit requests has become part of ordinary operations.
Pharmaceuticals. They're the category with the most rigorous regime. A pharmaceutical product isn't simply "registered" — it undergoes formal approval (New Drug Application), a multi-year process that involves clinical trials and FDA technical review. For Italian pharmaceutical companies, it's a specialist terrain that's tackled with dedicated structures and significant investments. It isn't an area of "registration" in the administrative sense, it's an area of substantial authorization.
Medical devices. They have an intermediate regime. They're classified into three classes based on the level of risk. Class I devices (low risk) generally require only registration and product listing. Class II devices (medium risk) require in many cases a prior notification through the 510(k) procedure, in which the manufacturer demonstrates that the device is "substantially equivalent" to a device already approved on the market. Class III devices (high risk) require Premarket Approval (PMA), a process similar to that of drugs. For Italian companies that produce medical devices, the critical initial phase is the correct classification of their product, which determines the entire regulatory path. Classification errors can cost years.
Cosmetics. Historically the category with the lightest regime, it has been affected in recent years by a significant reform that has aligned the obligations of cosmetics producers to a level much more similar to that of other sectors. Registration of facilities, listing of products, appointment of a responsible person in the United States, reporting of serious adverse events, compliance with Good Manufacturing Practices: these are all requirements that until a few years ago didn't apply. For Italian cosmetics companies, particularly the niche ones that export to the United States, it's a substantial change in administrative burden that deserves adequate preparation. Continuing to operate as they operated before is a position progressively exposed to problems.
The process, in practice
FDA registration for an Italian company follows standard steps that it's useful to articulate with operational precision, because many companies waste time tackling them in a disorderly way.
Correct identification of the product. The first step is to understand exactly which FDA category your product falls into, and which specific regime applies. Categorization errors at this stage generate cascading problems that are hard to correct later. For borderline products — a functional food that could fall under supplements or under drugs, a cosmetic that makes a claim on the edge of the medical, a medical device that could be classified in two different classes — specialized consulting is worthwhile before even starting any formal procedure.
Appointing the US Agent. All non-US companies subject to FDA registration must appoint an agent resident in the United States who acts as the official point of contact with the agency. It isn't a cosmetic role — the US Agent receives official communications, manages FDA requests for information, coordinates the response to any inspections. Choosing it well is important: generic agents at the lowest price are often a false economy. Agents specialized in the specific sector cost more but make the difference in complex operational situations.
Registering the facilities. The company registers each of its production facilities in the FDA Facility Registration Database, providing detailed information on location, production capacity, products, certifications. The registration must be renewed periodically (with variable frequency depending on the sector) and updated whenever relevant information changes.
Listing the products. For some categories (medical devices, cosmetics under the new rules, drugs), in addition to facility registration, the specific listing of each product placed on the American market is required.
Documentary compliance. Companies must maintain complete documentation of production processes, safety tests, raw materials used, supply-chain traceability. This documentation isn't normally sent to the FDA — it's kept available and produced in case of inspection or specific request. The quality of this documentation is what makes the difference in case of an audit.
Labeling compliance. Product labeling for the American market follows specific rules, different from the European ones. Language, mandatory content, formats, permitted and non-permitted claims, category-specific warnings: everything is regulated. Labeling errors are one of the most frequent causes of blocks at customs entry.
Prior Notice (for food). For each shipment of food destined for the United States, a Prior Notice is required that precedes the arrival of the goods. Errors or delays in the notice produce blocks and costs.
What FDA registration doesn't solve
While necessary, FDA registration doesn't solve several things that people often think it solves. It's worth naming them, because they're a recurring source of unpleasant surprises.
It doesn't constitute a commercial credential. On the American market, "FDA registered" doesn't mean "FDA approved" and isn't read by informed customers as a competitive advantage. Companies that present themselves emphasizing registration as an element of value often signal their own inexperience.
It doesn't guarantee product acceptance at customs. Documentary compliance with FDA registration is a necessary but not sufficient condition for customs entry. Specific checks at the port of entry can identify compliance problems that hadn't emerged in the registration, from labeling to composition, to consistency with what was declared.
It doesn't protect against third-party challenges. Competitors, consumer associations, state authorities can report specific practices of a company to the FDA, triggering checks that go beyond formal registration. Substantial compliance counts more than formal compliance.
It doesn't replace the quality certifications relevant to the segment. For many products that seek to position themselves in the premium segments of the American market, certifications like USDA Organic for organic food, Non-GMO Project for non-GMO products, sustainability certifications, traceability marks are what actually builds commercial differentiation. The FDA is the prerequisite; these certifications are what produces market value.
The certifications that produce commercial value in the US
For Italian companies that want to position themselves seriously on the American market, it's worth articulating the certifications that have commercial relevance, distinct from FDA registration.
USDA Organic is the US organic certification, managed by the Department of Agriculture. For Italian organic agri-food companies that sell in the United States, it's a certification that has concrete commercial value. There's a reciprocity agreement between USDA Organic and the European organic system that simplifies recognition, but with specifics that must be verified case by case.
ISO certifications maintain a baseline value in many industrial sectors. ISO 9001 for quality management, ISO 14001 for environmental management, ISO 22000 for food safety are often prerequisites to qualify as a supplier to US industrial groups. They don't produce commercial differentiation but their absence excludes.
Sustainability and social-responsibility certifications — B Corp, Fair Trade, Rainforest Alliance, verified carbon-neutrality certifications — have growing value on the American market in specific segments. The choice must be consistent with the sector and the target markets — accumulating generic certifications produces cost without return.
Niche certifications relevant to the product. For every sector there are specific certifications that the American market recognizes as quality signals. Kosher and Halal for those who want to cover those segments, verified gluten-free certifications, vegan certifications, NSF International for products that come into contact with food, UL for electrical safety. Identifying the three or four certifications that your market segment really recognizes is a strategic exercise worth doing with care.
What AI tools have changed in FDA preparation
FDA preparation is an area where AI tools have produced significant advantages in recent years, particularly accessible to medium and small companies that until recently had to rely entirely on costly external consulting.
Preliminary identification of product classification can today be done much more accurately thanks to AI tools that have digested the FDA guidelines and that can produce preliminary categorization analyses of a specific product. They don't replace verification with specialized consulting on borderline cases, but they drastically reduce the initial learning curve.
Analysis of the required documentation is an activity that AI can support effectively. Verifying whether the documentation of your product is consistent with FDA requirements, identifying gaps, flagging inconsistencies between declarations — these are tasks that AI tools perform well and that make it possible to arrive at the interaction with external consulting with a much higher level of preparation.
Ongoing regulatory monitoring is an area where AI significantly changes the economics of the process. FDA regulation is in constant evolution — new guidance, changes to procedures, updates on specific categories. Maintaining ongoing awareness of what's changing previously required dedicated regulatory offices. Today it can be structured as an automated service with human verification on the critical points.
Preparing for inspections can be supported by AI simulations that help identify the most vulnerable areas of your documentation and processes, so as to arrive at a possible FDA inspection with awareness of your weak points.
What remains human — and indispensable — is the role of specialized consulting for complex decisions, formal interaction with the agency, defense in case of challenges. But the preliminary filter, the preparation, the ongoing monitoring, are today activities that can be structured sustainably even for companies of contained size.
FDA registration is the entry ticket to the American market for regulated products. Nothing more, nothing less. Companies that treat it as a quality certification present themselves on the market in a way that signals inexperience to informed customers. Companies that underestimate it as bureaucratic paperwork find themselves managing operational problems that could have been avoided with adequate preparation.
The operationally sensible approach is the one that recognizes FDA registration for what it is — a necessary condition for being on the market — and builds on top of it the structure of certifications, positioning, and documentary quality that actually produces commercial value. The Italian companies that have built lasting presences on the American market have substantially done this: they've managed FDA registration with rigor without emphasizing it, and they've invested in what actually differentiates an Italian supplier from just any other on the US market — verifiable quality, certifications relevant to their segment, the ability to respond to American buyers' documentary requests with the precision the market expects.
Everything else — the commercial materials that display registration as a trophy, the presentations that confuse it with product approval, the commercial strategies that use it as a selling argument — are manifestations of the same basic mistake. The American market rewards substance. Approvals only serve to be able to enter it.